US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Articles published by Small Pharma Inc.

News headline image
Small Pharma Reports Fiscal Second Quarter 2024 Highlights
From Small Pharma Inc.
Via GlobeNewswire
Tickers DMTTF TSX-V:DMT
News headline image
Small Pharma Announces Voting Results from Annual General and Special Meeting of Shareholders
From Small Pharma Inc.
Via GlobeNewswire
Tickers DMTTF TSX-V:DMT
News headline image
Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder
From Small Pharma Inc.
Via GlobeNewswire
Tickers DMTTF TSX-V:DMT
News headline image
Small Pharma Reports Fiscal First Quarter 2024 Highlights
From Small Pharma Inc.
Via GlobeNewswire
Tickers DMTTF TSX-V:DMT
News headline image
Small Pharma Announces SPL028 R&D Strategy Update
From Small Pharma Inc.
Via GlobeNewswire
Tickers DMTTF TSX-V:DMT
News headline image
Small Pharma Announces Management Team Change
From Small Pharma Inc.
Via GlobeNewswire
Tickers DMTTF TSX-V:DMT
News headline image
Small Pharma Reports Financial Results for the Fiscal Year Ended February 28, 2023 and Recent Business Highlights
From Small Pharma Inc.
Via GlobeNewswire
Tickers DMTTF TSX-V:DMT
News headline image
Small Pharma Announces Significant Developments In Intellectual Property Portfolio
From Small Pharma Inc.
Via GlobeNewswire
Tickers DMTTF TSX-V:DMT
News headline image
Small Pharma to Present at Upcoming CINP World Congress of Neuropsychopharmacology
From Small Pharma Inc.
Via GlobeNewswire
Tickers DMTTF TSX-V:DMT
News headline image
Small Pharma Announces Positive Six-month Data from Phase IIa Trial of SPL026
From Small Pharma Inc.
Via GlobeNewswire
Tickers DMTTF TSX-V:DMT
News headline image
Small Pharma to Host Virtual Roundtable Event with Key Opinion Leaders in Psychiatry
From Small Pharma Inc.
Via GlobeNewswire
Tickers DMTTF TSX-V:DMT
News headline image
Small Pharma Announces Further Positive Data from SPL026 Phase IIa Trial in Major Depressive Disorder Strengthening Topline Efficacy Results
From Small Pharma Inc.
Via GlobeNewswire
Tickers DMTTF TSX-V:DMT
News headline image
Small Pharma to Present at Cowen’s 43rd Annual Health Care Conference
From Small Pharma Inc.
Via GlobeNewswire
Tickers DMTTF TSX-V:DMT
News headline image
First Subject Dosed in Small Pharma’s First-in-Human Phase I Clinical Trial with SPL028
From Small Pharma Inc.
Via GlobeNewswire
Tickers DMTTF TSX-V:DMT
News headline image
Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue
From Small Pharma Inc.
Via GlobeNewswire
Tickers DMTTF TSX-V:DMT
News headline image
Small Pharma Reports Fiscal Third Quarter 2023 Highlights
From Small Pharma Inc.
Via GlobeNewswire
Tickers DMTTF TSX-V:DMT
News headline image
Small Pharma Reports Positive Top-line Results from Phase IIa Trial of SPL026 in Major Depressive Disorder
From Small Pharma Inc.
Via GlobeNewswire
Tickers DMTTF TSX-V:DMT
News headline image
Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25
From Small Pharma Inc.
Via GlobeNewswire
Tickers DMTTF TSX-V:DMT
News headline image
First Patient Dosed in Small Pharma’s Phase I Study Exploring Intramuscular Administration of SPL026
From Small Pharma Inc.
Via GlobeNewswire
Tickers DMTTF TSX-V:DMT
News headline image
Small Pharma Announces Completion of SPL026 Phase IIa Trial and Secures New Intellectual Property
From Small Pharma Inc.
Via GlobeNewswire
Tickers DMTTF TSX-V:DMT
News headline image
First Patient Dosed in Small Pharma’s Drug Interaction Study
From Small Pharma Inc.
Via GlobeNewswire
Tickers DMTTF TSX-V:DMT
News headline image
Small Pharma To Support University College London Research Project on Neuroplasticity
From Small Pharma Inc.
Via GlobeNewswire
Tickers DMTTF TSX-V:DMT
News headline image
Small Pharma to Participate in Upcoming Canaccord Genuity Investor Symposium
From Small Pharma Inc.
Via GlobeNewswire
Tickers DMTTF TSX-V:DMT
News headline image
Small Pharma to Participate in November Investor and Healthcare Conferences
From Small Pharma Inc.
Via GlobeNewswire
Tickers DMTTF TSX-V:DMT
News headline image
Small Pharma Receives Approval for First-In-Human Phase I Clinical Trial With SPL028
From Small Pharma Inc.
Via GlobeNewswire
Tickers DMTTF TSX-V:DMT
News headline image
Second United States Patent Granted for Small Pharma’s Psychedelics Portfolio
From Small Pharma Inc.
Via GlobeNewswire
Tickers DMTTF TSX-V:DMT
News headline image
Small Pharma Reports Fiscal Second Quarter 2023 Highlights
From Small Pharma Inc.
Via GlobeNewswire
Tickers DMTTF TSX-V:DMT
News headline image
U.S. Patent Grant to Strengthen Small Pharma’s DMT Patent Strategy With Injectable Formulation
From Small Pharma Inc.
Via GlobeNewswire
Tickers DMTTF TSX-V:DMT
News headline image
Small Pharma Inc.: World’s First Clinical Trial For DMT-Assisted Therapy in Major Depressive Disorder Shows Consistent Quality of Psychedelic Response in Phase I
From Small Pharma Inc.
Via Business Wire